Wedekind, Dirk

[["dc.bibliographiccitation.firstpage","809"],["dc.bibliographiccitation.issue","8"],["dc.bibliographiccitation.journal","European Archives of Psychiatry and Clinical Neuroscience"],["dc.bibliographiccitation.lastpage","817"],["dc.bibliographiccitation.volume","268"],["dc.contributor.author","Krech, Lisa"],["dc.contributor.author","Belz, Michael"],["dc.contributor.author","Besse, Matthias"],["dc.contributor.author","Methfessel, Isabel"],["dc.contributor.author","Wedekind, D."],["dc.contributor.author","Zilles, David"],["dc.date.accessioned","2019-02-26T10:15:46Z"],["dc.date.available","2019-02-26T10:15:46Z"],["dc.date.issued","2018"],["dc.description.abstract","Electroconvulsive therapy (ECT) is the most effective therapy for severe depressive disorders. Though there are known clinical predictors of response (e.g., higher age, presence of psychotic symptoms), there is a lack of knowledge concerning the impact of patients' expectations on treatment outcome and tolerability in terms of possible placebo/nocebo effects. In 31 patients with unipolar or bipolar depressive disorder, we used a questionnaire to investigate the patients' expectations of ECT effectiveness and tolerability prior to and in the course of the treatment. Additionally, the questionnaire was used after the ECT course for a final assessment. Depressive symptoms and putative side-effects were measured at each time point. General linear models were used to analyze the course of depressive symptoms and patients' expectation of ECT effectiveness and tolerability. ECT significantly reduced depressive symptoms with large effect sizes. Patients' rating of ECT effectiveness decreased in parallel: While responders' rating of ECT effectiveness remained stable on a high level, non-responders' rating decreased significantly. Group difference was significant after, but not prior to and during the treatment. Regarding tolerability, there was a (temporary) significant increase in the severity of self-rated symptoms such as headache and memory impairment. In contrast, patients' expectation and assessment of ECT tolerability remained unchanged, and their expectations prior to ECT had no impact on the occurrence of side-effects. These findings contradict the presence of relevant placebo/nocebo effects in the context of ECT when investigating a population of mostly chronic or treatment resistant patients with moderate to severe depressive disorder."],["dc.identifier.doi","10.1007/s00406-017-0840-8"],["dc.identifier.eissn","1433-8491"],["dc.identifier.pmid","28940099"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/57612"],["dc.language.iso","en"],["dc.notes.status","final"],["dc.title","Influence of depressed patients' expectations prior to electroconvulsive therapy on its effectiveness and tolerability (Exp-ECT): a prospective study"],["dc.type","journal_article"],["dc.type.internalPublication","unknown"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","42"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","ZEITSCHRIFT FUR PSYCHOSOMATISCHE MEDIZIN UND PSYCHOTHERAPIE"],["dc.bibliographiccitation.lastpage","57"],["dc.bibliographiccitation.volume","47"],["dc.contributor.author","Doering, Stefan"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Pilz, J."],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Adler, L."],["dc.contributor.author","Huether, Gerald"],["dc.date.accessioned","2018-11-07T09:41:12Z"],["dc.date.available","2018-11-07T09:41:12Z"],["dc.date.issued","2001"],["dc.description.abstract","Cortisol is one of the major parameters investigated in psychoneuroendocrinological research, but the methods employed for sample collecting are often unsatisfactory, A suitable method of sample collection should allow for the integrative assessment of long-term changes of the HPA-system, should be non-invasive, and should not exceed the subject's compliance. The assessment of cortisol in night-urine fulfils these demands; although this method has been occasionally employed, it has not yet been described systematically, For the first time a detailed description is given here that allows for a standardized replication. In ten previous studies and three investigations of our own this method has been successfully applied to detect changes in the cortisol excretion of patients with endocrinological and psychiatric disorders as well as in subjects under conditions of psychosocial stress. The determination of cortisol in night-urine represents an ideal method for the assessment of changes in the basal HPA-activity in numerous areas of psychoneuroendocrinological research, e.g. field and screening studies in natural environment, clinical studies in psychiatry and especially follow-up studies in psychotherapy research."],["dc.identifier.isi","000166985000003"],["dc.identifier.pmid","11593453"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33678"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Vandenhoeck & Ruprecht"],["dc.relation.issn","1438-3608"],["dc.title","Cortisol in night-urine: Introduction of a research method in psychoneuroendocrinology"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Pharmacopsychiatry"],["dc.bibliographiccitation.volume","44"],["dc.contributor.author","Zilles, David"],["dc.contributor.author","Zerr, I."],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2018-11-07T08:52:01Z"],["dc.date.available","2018-11-07T08:52:01Z"],["dc.date.issued","2011"],["dc.identifier.doi","10.1055/s-0031-1292566"],["dc.identifier.isi","000296086300150"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22068"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.conference","27th Symposium of the AGNP"],["dc.relation.eventlocation","Munich, GERMANY"],["dc.relation.issn","0176-3679"],["dc.title","Effectiveness of donepezil in the treatment of musical hallucinations: evidence from case reports and pathophysiological considerations"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","European Psychiatry"],["dc.bibliographiccitation.volume","25"],["dc.contributor.author","Croissant, B."],["dc.contributor.author","Boehler, J."],["dc.contributor.author","Lorenz, Jan L."],["dc.contributor.author","Diehl, A."],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Mann, K."],["dc.contributor.author","Havemann-Reinecke, Ursula"],["dc.date.accessioned","2018-11-07T08:47:37Z"],["dc.date.available","2018-11-07T08:47:37Z"],["dc.date.issued","2010"],["dc.identifier.isi","000208225801265"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20999"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier France-editions Scientifiques Medicales Elsevier"],["dc.publisher.place","Paris"],["dc.relation.issn","0924-9338"],["dc.title","RCT: QUETIAPINE VS. PLACEBO IN ALCOHOL RELAPSE PREVENTION. RATIONAL, METHODS AND PRELIMINARY RESULTS"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","616"],["dc.bibliographiccitation.issue","10"],["dc.bibliographiccitation.journal","Fortschritte der Neurologie · Psychiatrie"],["dc.bibliographiccitation.lastpage","620"],["dc.bibliographiccitation.volume","76"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Engel, Katharina"],["dc.contributor.author","Bandelow, Borwin"],["dc.date.accessioned","2018-11-07T11:10:31Z"],["dc.date.available","2018-11-07T11:10:31Z"],["dc.date.issued","2008"],["dc.identifier.doi","10.1055/s-2008-1038201"],["dc.identifier.isi","000260387300013"],["dc.identifier.pmid","18833508"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53227"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0720-4299"],["dc.title","Social Anxiety Disorder - Diagnostics and Treatment Options"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","203"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Journal of Alzheimer's Disease"],["dc.bibliographiccitation.lastpage","212"],["dc.bibliographiccitation.volume","62"],["dc.contributor.author","Vogelgsang, Jonathan"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bouter, Caroline"],["dc.contributor.author","Klafki, Hans-W."],["dc.contributor.author","Wiltfang, Jens"],["dc.date.accessioned","2020-12-10T18:44:11Z"],["dc.date.available","2020-12-10T18:44:11Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.3233/JAD-170793"],["dc.identifier.eissn","1875-8908"],["dc.identifier.issn","1387-2877"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/78359"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Reproducibility of Alzheimer’s Disease Cerebrospinal Fluid-Biomarker Measurements under Clinical Routine Conditions"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","635"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Der Nervenarzt"],["dc.bibliographiccitation.lastpage","644"],["dc.bibliographiccitation.volume","85"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2018-11-07T09:40:47Z"],["dc.date.available","2018-11-07T09:40:47Z"],["dc.date.issued","2014"],["dc.description.abstract","With a lifetime prevalence of 13 % social phobia (social anxiety disorder) is a common and serious condition that should not be played down because of the burden associated with the disorder, an increased suicide rate and the frequent comorbidity with substance abuse disorders. Social phobia is characterized by the excessive and unrealistic fear of being scrutinized or criticized by others. The disorder often begins in adolescence. Symptoms of social phobia can be effectively treated with evidence-based treatment, including cognitive behavior therapy (CBT) and psychopharmacological medications. In the present paper, treatment recommendations are given, which are based on a systematic review of all available randomized trials for the treatment of social phobia. Among psychological therapies, variants of CBT have been proven to be effective in controlled studies. Selective serotonin reuptake inhibitors (SSRIs) and the selective serotonin norepinephrine reuptake inhibitor (SNRI) venlafaxine are among the drugs of first choice."],["dc.identifier.doi","10.1007/s00115-013-3955-9"],["dc.identifier.isi","000335660700017"],["dc.identifier.pmid","24718882"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/33576"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.relation.issn","1433-0407"],["dc.relation.issn","0028-2804"],["dc.title","Social phobia"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","831"],["dc.bibliographiccitation.issue","7"],["dc.bibliographiccitation.journal","Journal of Neural Transmission"],["dc.bibliographiccitation.lastpage","837"],["dc.bibliographiccitation.volume","107"],["dc.contributor.author","Wedekind, Dirk"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Broocks, Andreas"],["dc.contributor.author","Hajak, Goran"],["dc.contributor.author","Ruther, Eckart"],["dc.date.accessioned","2018-11-07T11:09:47Z"],["dc.date.available","2018-11-07T11:09:47Z"],["dc.date.issued","2000"],["dc.description.abstract","Background. Research on basal HPA axis activity in patients with panic disorder showed inconsistent results. Methods. Basal total plasma, plasma free and salivary cortisol levels were compared in patients with panic disorder (n = 47) and in healthy individuals (n = 23). Correlations between these fractions were calculated. Results. All three basal cortisol fractions were significantly elevated in patients compared to controls. There were significant correlations between all three cortisol fractions. Conclusions. Nonsignificant differences between cortisol levels of patients and healthy controls in previous studies may have been due to inclusion of less severely ill patients or to small sample sizes (96 words)."],["dc.identifier.doi","10.1007/s007020070062"],["dc.identifier.isi","000088415100008"],["dc.identifier.pmid","11005547"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/53083"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Springer"],["dc.publisher.place","Wien"],["dc.relation.issn","0300-9564"],["dc.title","Salivary, total plasma and plasma free cortisol in panic disorder"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","333"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","The British Journal of Psychiatry"],["dc.bibliographiccitation.lastpage","338"],["dc.bibliographiccitation.volume","212"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Sagebiel, Anne"],["dc.contributor.author","Belz, Michael"],["dc.contributor.author","Görlich, Yvonne"],["dc.contributor.author","Michaelis, Sophie"],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2020-12-10T18:41:28Z"],["dc.date.available","2020-12-10T18:41:28Z"],["dc.date.issued","2018"],["dc.identifier.doi","10.1192/bjp.2018.49"],["dc.identifier.eissn","1472-1465"],["dc.identifier.issn","0007-1250"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/77588"],["dc.language.iso","en"],["dc.notes.intern","DOI Import GROB-354"],["dc.title","Enduring effects of psychological treatments for anxiety disorders: meta-analysis of follow-up studies"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","393"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Human Psychopharmacology Clinical and Experimental"],["dc.bibliographiccitation.lastpage","415"],["dc.bibliographiccitation.volume","30"],["dc.contributor.author","Bandelow, Borwin"],["dc.contributor.author","Wedekind, Dirk"],["dc.date.accessioned","2018-11-07T09:49:33Z"],["dc.date.available","2018-11-07T09:49:33Z"],["dc.date.issued","2015"],["dc.description.abstract","Around half the inmates in prison institutions have antisocial personality disorder (ASPD). A recent theory has proposed that a dysfunction of the endogenous opioid system (EOS) underlies the neurobiology of borderline personality disorder (BPD). In the present theoretical paper, based on a comprehensive database and hand search of the relevant literature, this hypothesis is extended to ASPD, which may be the predominant expression of EOS dysfunction in men, while the same pathology underlies BPD in women. According to evidence from human and animal studies, the problematic behaviours of persons with antisocial, callous, or psychopathic traits may be seen as desperate, unconscious attempts to stimulate their deficient EOS, which plays a key role in brain reward circuits. If the needs of this system are not being met, the affected persons experience dysphoric mood, discomfort, or irritability, and strive to increase binding of endogenous opioids to receptors by using the rewarding effects of aggression by exertion of physical or manipulative power on others, by abusing alcohol or substances that have the reward system as target, by creating an endorphin rush by self-harm, by increasing the frequency of their sexual contacts, or by impulsive actions and sensation seeking. Symptoms associated with ASPD can be treated with opioid antagonists like naltrexone, naloxone, or nalmefene. Copyright (c) 2015 John Wiley & Sons, Ltd."],["dc.identifier.doi","10.1002/hup.2497"],["dc.identifier.isi","000364641400001"],["dc.identifier.pmid","26250442"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/35531"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1099-1077"],["dc.relation.issn","0885-6222"],["dc.title","Possible role of a dysregulation of the endogenous opioid system in antisocial personality disorder"],["dc.type","review"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]